10x Genomics
30-Second Executive Brief
Executive Assessment
10x Genomics functions as a regional institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, with a stable competitive position.
- Maintains 2 mapped relationships across the graph
- 55% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 55%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Steady
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A life-science instruments company specializing in single-cell and spatial genomics, reporting Q2 2026 revenue of $151.0 million and raising full-year 2026 guidance to $610-$630 million. The company acquired Proteintech Genomics to add protein-detection capabilities to its multiomics platform, and reported strong early customer response and order flow for its new Atera product, alongside new multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital on diagnostic applications in cancer care.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- 10x Genomics — 10x Genomics acquires Proteintech Genomicscompany
- PR Newswire — 10x Genomics reports second quarter 2026 financial resultscompany
Latest Activity
- Filing10x Genomics filed an 8-K (items 2.02,9.01)8-K
- Filing10x Genomics insider selling — $1,155,055 saleForm 4
- Filing10x Genomics insider selling — $870,860 saleForm 4
- Filing10x Genomics insider selling — $1,081,853 saleForm 4
- Filing10x Genomics insider selling — $1,168,775 saleForm 4
- Filing10x Genomics insider selling — $667,901 saleForm 4
Insider Filing Activity
Direction/size reflects a sample of the most recent filings, not every Form 4 in the window · sourced from SEC EDGAR · as of Sep 7, 2026
Insider Timing
An insider disposed of 492 shares on Aug 26, 2026 — 25 days after a recorded milestone: “Q2 2026: revenue $151.0M, guidance raised to $610-630M”
Timing correlation only — not evidence of a causal link
An insider disposed of 6,494 shares on Aug 26, 2026 — 25 days after a recorded milestone: “Q2 2026: revenue $151.0M, guidance raised to $610-630M”
Timing correlation only — not evidence of a causal link
An insider disposed of 3,500 shares on Aug 26, 2026 — 25 days after a recorded milestone: “Q2 2026: revenue $151.0M, guidance raised to $610-630M”
Timing correlation only — not evidence of a causal link
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding 10x Genomics — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
10x Genomics' guidance raise is encouraging, but the underlying growth rate excluding one-time items is more modest
32% confidence10x Genomics raised full-year 2026 guidance to $610-630 million on strong early demand for its new Atera product and the Proteintech Genomics acquisition, while the company's own disclosure notes revenue excluding one-time patent-settlement income shows only modest single-digit growth.
This is InsightNodes' own interpretive read: the guidance raise and Atera product enthusiasm are genuinely positive signals, but investors should distinguish between the headline growth trajectory and the underlying single-digit core commercial momentum once one-time patent-settlement income is excluded -- this mirrors the broader academic-research-funding headwind affecting life-science-instruments peers like Bio-Rad and Thermo Fisher, and Atera's early order flow will need to convert into sustained recurring revenue to meaningfully lift the underlying growth rate rather than just the headline guidance figure.
InsightNodes analysis of 10x Genomics Q2 2026 results · Aug 14, 2026
10x Genomics's Timeline
A sourced, dated history of 10x Genomics's key moments — founding to present.
May 2026 · Acquires Proteintech Genomics
10x Genomics acquired Proteintech Genomics, adding advanced protein-detection capabilities to its single-cell and spatial multiomics platform.
Aug 2026 · Q2 2026: revenue $151.0M, guidance raised to $610-630M
10x Genomics reported Q2 2026 revenue of $151.0 million and raised full-year 2026 guidance to $610-$630 million, citing strong early customer response to its new Atera product.